U.S. federal judges upheld patent related to Abilify (Aripiprazole) marketed by Bristol-Myers Squibb Co. The concenr patent US 5006528, which claims compound Aripiprazole and having expiry on Apr 20, 2015 with pediatric exclusivity. Due to this decision the generic players can not enter the market before Apr 20, 2015.
Abilify is the second highest selling drug in BMS portfolio presently. So this decision is a victory for them.
(source: http://uk.reuters.com)
No comments:
Post a Comment